HomeCompareAMPE vs NOBL

AMPE vs NOBL: Dividend Comparison 2026

AMPE yields 1311.05% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMPE wins by $207537754.83M in total portfolio value
10 years
AMPE
AMPE
● Live price
1311.05%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207537754.85M
Annual income
$180,460,634,612,456.80
Full AMPE calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — AMPE vs NOBL

📍 AMPE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMPENOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMPE + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMPE pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMPE
Annual income on $10K today (after 15% tax)
$111,438.87/yr
After 10yr DRIP, annual income (after tax)
$153,391,539,420,588.28/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, AMPE beats the other by $153,391,539,420,375.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMPE + NOBL for your $10,000?

AMPE: 50%NOBL: 50%
100% NOBL50/50100% AMPE
Portfolio after 10yr
$103768877.44M
Annual income
$90,230,317,306,353.30/yr
Blended yield
86.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMPE right now

AMPE
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-63.7
Piotroski
3/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMPE buys
0
NOBL buys
0
No recent congressional trades found for AMPE or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMPENOBL
Forward yield1311.05%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$207537754.85M$22.9K
Annual income after 10y$180,460,634,612,456.80$249.78
Total dividends collected$205538221.53M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AMPE vs NOBL ($10,000, DRIP)

YearAMPE PortfolioAMPE Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$141,805$131,104.56$10,917$217.08+$130.9KAMPE
2$1,889,228$1,737,497.51$11,903$221.48+$1.88MAMPE
3$23,655,368$21,633,893.61$12,962$225.68+$23.64MAMPE
4$278,471,869$253,160,624.79$14,099$229.68+$278.46MAMPE
5$3,083,213,738$2,785,248,838.88$15,319$233.49+$3083.20MAMPE
6$32,119,606,169$28,820,567,469.38$16,628$237.10+$32119.59MAMPE
7$314,966,468,315$280,598,489,713.88$18,033$240.53+$314966.45MAMPE
8$2,908,568,193,145$2,571,554,072,047.85$19,539$243.78+$2908568.17MAMPE
9$25,305,719,846,817$22,193,551,880,152.03$21,154$246.86+$25305719.83MAMPE
10$207,537,754,848,551$180,460,634,612,456.80$22,884$249.78+$207537754.83MAMPE

AMPE vs NOBL: Complete Analysis 2026

AMPEStock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Full AMPE Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this AMPE vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMPE vs SCHDAMPE vs JEPIAMPE vs OAMPE vs KOAMPE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.